Nuclear bile acid receptor FXR in the hepatic regeneration  by Chen, Wei-Dong et al.
Biochimica et Biophysica Acta 1812 (2011) 888–892
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isReview
Nuclear bile acid receptor FXR in the hepatic regeneration☆
Wei-Dong Chen 1, Yan-Dong Wang 1, Zhipeng Meng, Lisheng Zhang, Wendong Huang ⁎
Division of Gene Regulation & Drug Discovery, Beckman Research Institute, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA☆ This article is part of a Special Issue entitled: Tran
health to disease.
⁎ Corresponding author. Tel.: +1 626 256 4673x6520
E-mail address: whuang@coh.org (W. Huang).
1 These authors contributed equally to this review.
0925-4439/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbadis.2010.12.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 September 2010
Received in revised form 6 December 2010
Accepted 8 December 2010
Available online 15 December 2010
Keywords:
FXR
Nuclear receptor
Bile acid
Liver regeneration
Liver repairThe liver can fully regenerate itself by a compensatory regrowth in response to partial hepatectomy or injury.
This process consists of a variety of well-orchestrated phases and is mediated by many signals. Farnesoid X
receptor (FXR) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription
factors. Bile acids are FXR physiological ligands. As a metabolic regulator, FXR plays key roles in regulating
metabolism of bile acids, lipids and glucose. Recently, bile acid/FXR signaling pathway is shown to be required
for normal liver regeneration. Furthermore, FXR promotes liver repair after injury and activation of FXR is able
to alleviate age-related defective liver regeneration. These novel ﬁndings suggest that FXR-mediated bile acid
signaling is an integrated component of normal liver regeneration machinery, and also highlight the potential
use of FXR ligands to promote liver regeneration after segmental liver transplantation or resection of liver
tumors. This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease.slating nuclear receptors from
3.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The liver is one of the few organs that can completely regenerate
itself in response to partial ablation or injury. Liver regeneration has
been studied intensively since the introduction of a rodent partial
hepatectomy (PH)model in 1931 [1]. This process consists of a variety
of well-orchestrated phases, and many signaling pathways and
transcription factors are involved in this process [2–5]. Although
many details of liver regeneration have been elucidated, the exact
signals that initiate, promote and terminate liver regeneration in
response to PH or liver injury remain elusive.
The regenerative capacity of the liver is adversely affected by
aging, which dramatically increases mortality in aging patients in
situations when the liver is resected as a result of malignancy, after
liver transplantation or after hepatic insult/injury [6–8]. Therefore,
there is an urgent medical need to develop drugs that can promote
liver regeneration in aged patients. Previous studies suggest that: 1)
aging mainly epigenetically suppresses liver regeneration and this
suppression is reversible; and 2) multiple pathways may work
independently to promote liver regeneration [9,10]. This thus
provides an opportunity to identify a particular pathway that can
promote aging liver regeneration without obvious adverse side
effects.
The farnesoid X receptor (FXR, NR1H4), initially cloned in 1995
[11], belongs to a sub-cluster of metabolic nuclear receptors that alsoincludes Vitamin D Receptor (VDR, NR1I1), Constitutive Androstane
Receptor (CAR, NR1I3), Pregnane X Receptor (PXR, NR1I2) and Liver X
Receptor alpha and beta (LXRα, NR1H3; LXRβ, NR1H2). As a
transcription factor, FXR binds to DNA either as a monomer or as a
heterodimer with retinoid X receptor (RXR, NR2B1) to regulate the
expression of various FXR target genes. FXR is highly expressed in the
liver, intestine, kidney and adrenals, but with much lower expression
in the adipose tissues and heart [11,12]. There are four isoforms of FXR
resulting from either differential use of two promoters or alternative
splicing [13,14]. In addition to working as a key metabolic regulator,
FXR has much broader functions than previously thought. For
example, FXR mediates bile acid signaling to promote normal liver
regeneration [15]. Moreover, FXR activation is shown to sufﬁciently
alleviate age-related proliferation defects in regenerating mouse
livers by directly activating the transcription of the Forkhead box
m1b (Foxm1b; previously known as HFH-11B, Trident, WIN, MPP2)
[6]. These novel ﬁndings suggest that FXR plays an important role in
hepatic regeneration.
In this review, wewill ﬁrst summarize the general functions of FXR
in metabolic regulation and then focus on its roles in hepatic
regeneration.
2. The nuclear bile acid receptor FXR
FXR's roles in metabolic regulation and metabolic diseases have
been summarized by a number of excellent reviews. Recently, several
new functions of FXR beyond metabolic regulation have been
identiﬁed [16–19]. FXR is the primary sensor of bile acids. In fact,
both conjugated and unconjugated bile salts are able to activate FXR at
physiological concentrations [17]. One of the primary bile acids,
chenodeoxycholic acid (CDCA) is a potent endogenous activator of
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acid (LCA), can both activate FXR but to a lesser extent than CDCA
does, whereas hydrophilic ursodeoxycholic (UDCA) and muricholic
acids cannot activate FXR [20]. FXR is activated by bile acidwith a rank
order of potency as CDCANDCANLCANcholic acid (CA) [21].
By binding to FXR responsive elements (FXREs), FXR regulates
many genes belonging to different metabolic pathways [22]. Over
the past decade, a number of studies on FXR have established FXR
as a key regulator of metabolism, which is reviewed by different
groups [23–26]. FXR is well known to regulate bile acid homeostasis
as well as the lipoprotein and glucose metabolism [27–37]. In
summary, FXR may act as a general sensor of metabolic stresses as
well as a modulator to regulate speciﬁc groups of gene expression
in order to provide hepatoprotection. However, recent studies
suggest that FXR also provides a second layer of hepatoprotection
through promoting liver regeneration and repair.3. FXR and liver regeneration
Liver regeneration is an adaptive response induced by speciﬁc
stimuli and includes subsequently sequential changes in gene
expression and morphologic reconstruction. It consists of a variety
of well orchestrated phases, with rapid induction of proliferative
factors that activate the quiescent hepatocytes and prime their
subsequent progression through the cell cycle, followed by re-
establishment of normal liver size and renewed hepatocyte quies-
cence [2]. The essential circuitry required for this process is deﬁned
mainly by three major networks: cytokine, growth factor and
metabolic signals [38]. Although many genes and signaling pathways
have been reported to be involved in liver regeneration, compared to
the cytokines and growth factors, little is known about the roles of
metabolic signals in liver regeneration.
The original studies have indicated that the initiating signals of
liver regeneration are in the circulation system [39]. This has been
demonstrated by many studies showing that different proliferative
signals in serum are upregulated after 70% PH [4,38]. Even until
recently, there are still some new factors that are being identiﬁed,
suggesting that more than a single signal is responsible for liver
regeneration. For example, a recent ﬁnding suggests that serotonin is
not only a neurotransmitter but also a hormone with various
extraneuronal functions. Lesurtel et al. reported that platelet-derived
serotonin is involved in the promotion of liver regeneration [40].
Matondo et al. further indicated that very low levels of serotonin in
blood are sufﬁcient for liver regeneration [41].
Although many factors are being identiﬁed, bile acids may be
the neglected signals required for liver regeneration. Bile acids are
end products from cholesterol catabolism and are essential for
normal intestine absorption of cholesterol, lipids and fat-soluble
vitamins [42]. Bile acids are synthesized in the liver and stored in
the gall bladder. They are secreted into the intestine when a meal
is ingested, but most bile acids (95%) are reabsorbed and
transported back to the liver through the portal vein. This system
is known as enterohepatic circulation. It has been known that
interrupting normal enterohepatic biliary circulation inhibits liver
regeneration and bile acids are able to stimulate hepatocyte
proliferation [43–45]. Moreover, hepatic bile acids comprise less
than 5% of the total bile acid pool and PH can increase bile ﬂow
[46,47]. These evidences suggest that bile acids may participate in
liver regeneration. Indeed, supplying the mice with a low dose of
bile acids promotes liver regeneration while reducing bile acid
levels by a bile acid binding resin delays liver regeneration [15].
This effect of bile acids is dependent on FXR activation because in
FXR null mice the observed effect disappears [15]. Therefore, it is
FXR that transforms the bile acid stress into the force of promoting
liver regeneration.4. FXR promotes liver repair after injury
The nature of FXR-mediated bile acid signaling in liver regener-
ation is a stress response. Feeding mice with a 1% CA diet during liver
regeneration is toxic and lethal, indicating that bile acids by nature are
not typical mitogens and the increased levels of bile acids activate FXR
to push liver regrowth in order to combat potential toxicity induced
by bile acids [48]. Indeed, a sharp reduced expression of CYP7a1 was
observed, the rate-limiting enzyme of bile acid production after 70%
PH [48]. In addition to FXR/SHP, during the early phase of liver
regeneration, MAPK and other pathways may also participate to
suppress the expression of CYP7a1. These results suggest that bile acid
stress is generated rapidly after 70% PH and there are multiple
mechanisms to accommodate this coming stress [48]. The roles of FXR
in liver regeneration were further investigated after injury by a liver
toxin, carbon tetrachloride (CCl4). In this study, FXR is further
conﬁrmed to be required to promote liver regeneration. Moreover,
since there is massive cell death in this model, FXR is also shown to
prevent hepatocytes from death [49]. The anti-apoptosis function of
FXR has been previously demonstrated. It was shown that FXR
activation speciﬁcally upregulated ERK pathways and protected liver
cells from apoptosis induced by serum deprivation in vitro and fasting
in vivo [19]. During liver repair after injury, this role of FXR in cell
survival may be linked to the activation of STAT3, which is a key factor
in cell survival [49]. Both cell proliferation and protection from
apoptosis are known to be important during liver regeneration or
repair. Therefore, the role of FXR in protecting hepatocytes from
apoptosis is consistent with its role to promote liver regeneration or
repair. However, the exact downstream events after FXR activation to
prevent cell apoptosis are still unclear and needs further investigation.
In summary, when liver is injured, FXR activation results in the down-
regulation of CYP7al, which help rapidly decrease hepatic bile acid
levels to protect the liver from apoptosis and necrosis induced by
elevated bile acid concentrations. At the same time, FXR promotes
liver regeneration for proper liver repair. The ability of FXR to promote
liver repair after injury is important to suppress hepatocarcinogen-
esis. Indeed, FXR null mice spontaneously develop liver tumors when
they age [50,51]. Without the roles of FXR in promoting liver repair
after injury, liver is prone to enter endless cycles of injury/repair that
will keep producing inﬂammatory cytokines and other growth factors
that are potential tumor promoters. Moreover, bile acids are known to
cause DNA damage and induce cell transformation if their levels are
not controlled by FXR. Therefore, FXR's role in promotion of liver
repair could be an intrinsic mechanism to protect liver from
carcinogenesis. We anticipate that delineation of the exact link
between FXR's roles in hepatoprotection and hepatocarcinogenesis is
an interesting area of future investigation.
In addition to liver, FXR is also highly expressed in intestine, which
is required to modulate bile acid homeostasis by suppressing CYP7a1
expression when bile acid levels are high [52]. Is intestine-FXR
involved in regulation of liver regeneration in response to PH or liver
injury? Activation of FXR increases the expression of FGF15 in the
ileum, which travels to liver to suppress CYP7a1 gene expression.
Does FGF15 contribute to liver regeneration? These questions need to
be answered to determine whether this endocrine pathway of FXR is
also participating in regulation of liver regeneration.
5. Nuclear receptor-mediated pathways in liver regeneration
As a member of the nuclear receptor superfamily, FXR mediates
the bile acid signaling to promote liver regeneration. In addition to
FXR, some other nuclear receptors have also been implicated in
regulating the process of liver regeneration. In 1984, Fisher et al. ﬁrst
showed that estrogen and its receptor-estrogen receptor affect liver
regeneration after PH [53]. Imai et al. showed that upon PH, liver
regeneration is impaired in mice lacking RXRα in hepatocytes [54].
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negative regulators of hepatocyte proliferation and might be
responsible for the inhibition of liver growth in the late phase of
liver regeneration [55]. Dai et al. indicated that the xenobiotic
receptor PXR is required for normal progression of liver regeneration
by modulating lipid homeostasis and regulating hepatocyte prolifer-
ation [56]. Another xenobiotic receptor CAR may be also involved in
regulating liver regeneration, although to a much less extent [15].
More recently, Lopez-Fontal reported that thyroid hormone receptor
contributes signiﬁcantly to the rapid initial round of hepatocyte
proliferation following PH, and improves the survival of the
regenerating liver at later stages [57]. These results indicate that the
increase of different endogenous metabolites and hormones during
liver regeneration may activate their individual receptor, which help
liver regeneration to different extent. However, the mechanisms by
which those receptors promote liver regeneration are largely
unknown. Actually, direct activation of some of these receptors such
as PPARα and CAR results in hepatomegaly quickly, which is distinct
from the normal liver regeneration [58]. The question is whether they
are all required for liver regeneration. The answer may be dependent
on the levels of endogenous ligands after 70% PH or liver injury.
Although all these nuclear receptors have the potential to be activated
and promote liver growth, only those whose endogenous ligands are
strongly increased, such as bile acids and FXR, will play major roles in
contribution to normal liver regeneration. Activation of FXR by its
ligand has been shown to promote liver regeneration in aged animals
[6], suggesting that further understanding of themechanism bywhich
nuclear receptors stimulate liver regrowth may provide novel
approaches to develop drugs for promotion of liver regeneration. In
summary, metabolic signaling is an integrated component of normal
liver regeneration. Multiple pathways are working in parallel to
contribute to the overall process of liver regeneration (Fig. 1).6. Promotion of the regeneration of aged liver by FXR activation
Although liver can fully regenerate itself, aging dramatically
reduces this capacity. The mechanism for the declined proliferative
capacity in aging liver is still unclear. According to the current
knowledge, the delayed and reduced proliferative response has been
attributed to the decreased expression of some key transcription
factors such as c-Myc and Foxm1b in response to liver ablation. This70% PH or liver injury
cytokines, growth factors metabolic signals
transcription factors nuclear receptors
Liver regeneration
Liver repair
······
Fig. 1. Multiple pathways are engaged in promoting liver regeneration. In addition to
cytokines and growth factors, metabolic signals are also generated during liver
regeneration, which activate their receptors to modulate the expression of a speciﬁc
group of genes involved in liver regeneration and repair.may be due to the appearance of an age-speciﬁc C/EBPα–Brm–HDAC1
protein complex in aging livers, which occupies the promoters of c-
Myc and Foxm1b to prevent their activation [9,10,59–61]. However,
studies from Costa's and Rando's groups indicated that either elevated
hepatocyte expression of Foxm1b [61,62] or diminished C/EBPα
complex through heterochronic parabiosis between young and old
mice [63] could help the aging liver proliferate after 70% PH. Foxm1b
is required for the timely expression of many cell cycle regulators
essential for G1/S and G2/M progression and chromosome stability
and segregation [64,65]. It is a key regulator of cell replication during
liver regeneration. Loss of Foxm1b function in livers of young mice
results in a signiﬁcant reduction in hepatocyte DNA replication and
inhibition of mitosis after PH [59]. More importantly, forced
expression of Foxm1b in regenerating livers of old mice is sufﬁcient
to restore hepatocyte DNA replication and expression of necessary cell
cycle regulatory genes to levels as seen in young animals [61,62].
These results highlight Foxm1b as one of the key regulators in liver
regeneration and indicate that activating Foxm1b may be sufﬁcient to
promote regeneration of aged liver.
The ability of an aged liver to regenerate can be restored by
exposing to growth hormone [62] or serum from young animals [63],
suggesting that aged liver cells retain their regenerative potency and
can be rejuvenated in response to the serum of young animals. It was
shown that there was a defective activation of FXR and diminished
binding of FXR to a FXRE in Foxm1b gene in aged regenerating livers
[6]. This suggests that untimely activation of FXR, resulting in
defective liver regeneration, could be an intrinsic defect in aged
regenerating livers. However, compared with young mice, aged mice
did not have altered protein levels of FXR and RXR. Therefore, aging
may reduce the levels of endogenous FXR ligands such as bile acids,
oxysterols, and other unknown factors [17], which could result in
defective activation of FXR in regeneration of aged liver. This is
conﬁrmed by the facts that treatments with synthetic FXR ligands are
sufﬁcient to induce Foxm1b gene expression and promote liver
regeneration in oldmice [6]. Whether FXR activation is able to remove
(HDAC1)–C/EBPα–E2F-Rb complex from Foxm1b promoter is worthy
of future investigation. However, it is still possible that FXR activates a
pathway independent of (HDAC1)–C/EBPα–E2F-Rb complex to
induce Foxm1b expression in aged livers.7. Conclusions and perspective
The function of FXR is expanded rapidly from initial roles in
controlling metabolism to regulating cell growth and malignancy.
However, the novel roles of FXR in promoting liver regeneration are
consistent with its previously deﬁned functions in regulating bile acid
metabolism and defending against liver toxicity. We hypothesize that
either resection or injury of liver will rapidly generate a bile acid stress
that may cause liver failure. The activation of FXR leads to a decrease
of bile acid levels in the liver, activates Foxm1b and other genes
involved in cell cycle progression, and promotes liver regrowth, which
helps accommodate and release the increased metabolic stresses.
Therefore, further understanding of the roles of FXR in hepatic
regeneration will provide novel insights into the complex mechanism
of this process.
The function of FXR to promote liver repair is also essential to
prevent hepatocarcinogenesis and other liver pathogenesis such as
ﬁbrosis. The prompt liver repair process will help liver to resumeFXR ligands FXR
improves liver metabolic functions
provides hepatic protection
promotes hepatic regeneration
Fig. 2. Multiple beneﬁcial effects of FXR ligands on liver regeneration.
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chronic injury and regeneration, which leads to chronic inﬂammation
and creates a liver environment to develop ﬁbrosis and cancer.
No effective therapies are currently available to promote liver
regeneration. Our studies indicate that FXR agonist ligands may offer
potential approaches to promote liver regeneration after segmental
liver transplantation or after resection of liver tumors. Using FXR
ligands to promote liver regeneration can have several advantages: 1)
FXR activation will improve liver metabolic functions; 2) prevent cell
death; and 3) directly promote liver regrowth (Fig. 2). We expect that
the development of more potent and safe FXR ligands will go into
clinical trials in the near future for those patients who need
accelerated liver regeneration after surgery.
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